Mironid® to attend BioEquity 2022

Mironid^® will be attending BioEquity in Milan, 16-18^th May 2022

Mironid’s CEO, Dr Neil Wilkie, will be attending Europe’s premier international showcase for financial dealmakers and biopharma executives in Milan’

The Latest

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026
At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]
Read more de Mironid Raises Awareness for PKD with 1,000 km Team Challenge
Q&A with David Henderson, Head of BiologyMarch 19, 2026
ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]
Read more de Q&A with David Henderson, Head of Biology
Allosteric modulation of long-form PDE4 enzymes, a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney DiseaseFebruary 18, 2026
Our Chief Scientific Officer, Adele Rowley, will be in London on 18 February for this year’s Ace Drug Discovery Summit, where she will be giving a presentation titled “Allosteric modulation of long-form PDE4 enzymes, a [...]
Read more de Allosteric modulation of long-form PDE4 enzymes, a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney Disease